Alzheimer's Disease Research Center

阿尔茨海默病研究中心

• 批准号: 10590691
• 负责人: Oscar L. Lopez
• 金额: $ 309.88万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-15 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10590691
• 关键词: Address; Adult; Advocacy; Altruism; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Area; Awareness; Basic Science; Behavioral Symptoms; Biological; Biological Markers; Biology; Blood; Brain; Caregivers; Caring; Clinic; Clinical; Clinical Course of Disease; Clinical Data; Clinical Research; Clinical assessments; Cognition; Cognition Disorders; Cognitive; Collaborations; Communication; Communities; Data; Data Collection; Databases; Dedications; Dementia; Development; Early Diagnosis; Early treatment; Education; Environment; Etiology; Evaluation; Evolution; Faculty; Family; Foundations; Functional disorder; Funding; Genetic; Goals; Grant; Healthcare; Heterogeneity; Human Resources; Image; Imaging technology; Individual; Infrastructure; Institution; International; Investments; Leadership; MRI Scans; Methodology; Methods; Motivation; Natural History; Nerve Degeneration; Neurobehavioral Manifestations; Outcome; Participant; Pathogenesis; Pathologic; Pathologic Processes; Patient Care; Patients; Pharmaceutical Preparations; Physicians; Positron-Emission Tomography; Process; Productivity; Protocols documentation; Psychoses; Public Health; Qualifying; Research; Research Personnel; Risk Factors; Role; Sampling; Scientist; Solid; Standardization; Students; Symptoms; Testing; Tracer; Training; Training Programs; Training and Education; Universities; Validation; career; cohort; data management; design; disease phenotype; education research; effective therapy; efficacious treatment; genetic risk factor; health care delivery; improved; innovation; insight; interdisciplinary approach; international center; member; mild cognitive impairment; multidisciplinary; neurogenetics; neuroimaging; neuropathology; neuropsychiatry; novel; novel therapeutics; outreach; outreach program; programs; recruit; research study

Overall: Summary/Abstract: The University of Pittsburgh Alzheimer’s Disease Research Center (PITT- ADRC) has shown a clear scientific evolution over the past three decades. Since our inception, we have advanced the areas of AD neuropsychiatry, genetics, natural history of AD, validation of clinical criteria, and clinico-pathological correlations, and have pioneered the development of PET amyloid tracers, which have transformed AD research. We have used a multidisciplinary approach to better understand the transition from normal cognition to dementia, have explored the biology of more aggressive forms of AD characterized by psychosis, and have made and contributed to new insights in genetics. This solid scientific background and investment in junior investigators has allowed the PITT-ADRC to develop areas of excellence, which form the foundation of our Center going forward. These are reflected in the Center’s cores, and most notably in the large number of studies we support in these areas in Pittsburgh and at national and international level. The PITT-ADRC is committed to remain at the forefront of the scientific efforts to understand the pathological processes involved in the etiology of AD. Along with the high level of research conducted by the PITT-ADRC, we are also dedicated to developing strong training programs to promote the careers of young investigators, consolidate the career of midlevel investigators, and to create strong ties with the community through educational and support programs. The PITT-ADRC is highly committed to leverage the strengths of the network of Centers to provide large numbers of samples and standardized clinical data collection from our participants. The PITT-ADRC has designed novel methodology that improves the accessibility of its database to local and national researchers, and it has been a key player in multiple studies that advanced the understanding of AD pathology and its possible implications for the development of novel treatments and other symptoms. Therefore, we provide an excellent environment that enhances cutting-edge research by bringing together a multidisciplinary team of investigators to study AD and other dementias, and to improve health care delivery. The methodology proposed in this application will lead us to the creation of a unique and well-characterized cohort of patients and normal control subjects assessed with state of the art clinical and biomarker methods. This will allow us to test multiple scientific hypotheses and to examine the short- and long-term public health outcomes of the pathophysiology of cognitive disorders in the adult. We believe that the PITT -ADRC will be at the center of the new era of AD research that will require a wealth of clinical and biological data, highly sophisticated biomarker methodologies, close inter-relationship among centers and institutions, creation and optimization of human resources, and enhanced communication with patients and families.

总体而言： 摘要/摘要： 匹兹堡大学阿尔茨海默病研究中心 (PITT- 自成立以来，ADRC）在过去的三十年中展现了明显的科学发展。 推进 AD 神经精神病学、遗传学、AD 自然史、临床标准验证等领域的发展 临床病理相关性，并率先开发了 PET 淀粉样蛋白示踪剂，该示踪剂已 我们采用了多学科方法来更好地理解 AD 研究的转变。 对痴呆症的正常认知，探索了更具侵袭性的 AD 形式的生物学，其特征是 精神病，并为遗传学的新见解做出了贡献。 对初级研究人员的投资使 PITT-ADRC 能够开发卓越领域，这些领域构成了 这些都体现在中心的核心中，最值得注意的是。 我们在匹兹堡以及国家和国际层面支持这些领域的大量研究。 PITT-ADRC 致力于保持在科学努力的最前沿，以了解 AD 病因学中涉及的病理过程以及 AD 的高水平研究。 PITT-ADRC，我们还致力于开发强大的培训计划，以促进年轻人的职业生涯 调查员，巩固中层调查员的职业生涯，并与社区建立牢固的联系 通过教育和支持计划。 PITT-ADRC 高度利用中心网络的优势，提供大量 PITT-ADRC 收集了我们参与者的样本数量和标准化临床数据。 设计了新颖的方法，提高了当地和国家研究人员对其数据库的可访问性， 它在多项研究中发挥了关键作用，促进了对 AD 病理学及其相关疾病的理解。 因此，我们提供了对新疗法和其他症状的开发可能的影响。 通过汇集多学科团队来增强尖端研究的优良环境 研究人员研究 AD 和其他痴呆症，并改善医疗保健服务。 本申请中提出的方法将引导我们创建一个独特且特征良好的 使用最先进的临床和生物标志物方法评估患者和正常对照受试者队列。 这将使我们能够测试多种科学假设并检查短期和长期的公共卫生 成人认知障碍的病理生理学结果。 我们相信 PITT-ADRC 将成为 AD 研究新时代的中心，这需要 丰富的临床和生物数据、高度复杂的生物标志物方法、密切的相互关系 各中心和机构之间，创建和优化人力资源，加强沟通 与患者和家属。